SEMAGLUTIDE
| Brand name | WEGOVY |
|---|---|
| Active ingredient | SEMAGLUTIDE |
| Strength | 0.5MG/0.5ML (0.5MG/0.5ML) |
| Dosage form | SOLUTION |
| Route | SUBCUTANEOUS |
| Modality | Small molecule |
| FDA approval | May 2026 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 11318191 | February 2041 | product |
| 11478533 | May 2040 | use U-3861 |
| 12029779 | October 2038 | use U-3162 |
| 12551536 | October 2038 | use U-4418 |
| 11752198 | August 2038 | product |
| 12214017 | August 2038 | product |
| 10888605 | August 2038 | product |
| 12569543 | April 2037 | use U-4443 |
| 9764003 | June 2033 | use U-3161 |
| 8129343 | December 2031 | substance, product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.